« previous next »
Pages: [1]

Author Topic: (AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT  (Read 82 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9549
  • MS diagnosed 1980
  • Location: Pacific Northwest
(AAN abst.) Impact of Tysabri switch to moderate vs. high-efficacy DMT
« on: May 11, 2019, 02:32:11 pm »
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
54 Views 		Last post April 17, 2019, 02:42:04 pm
by agate
1 Replies
64 Views 		Last post May 29, 2020, 09:45:07 pm
by agate
0 Replies
16 Views 		Last post March 22, 2020, 02:55:01 pm
by agate
0 Replies
64 Views 		Last post July 08, 2020, 08:37:07 pm
by agate
0 Replies
18 Views 		Last post July 02, 2021, 08:19:02 pm
by agate